BRIEF-Verastem Oncology Exercises Option Early to License VS-7375

Reuters01-14

Jan 14 (Reuters) - Verastem Inc :

* VERASTEM ONCOLOGY EXERCISES OPTION EARLY TO LICENSE VERSUS-7375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, FROM GENFLEET THERAPEUTICS AND PROVIDES PRELIMINARY CLINICAL UPDATE ON PHASE 1 STUDY IN CHINA

* VERASTEM INC - TO FILE U.S. IND APPLICATION FOR VERSUS-7375 IN Q1 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment